This review outlines the clinical presentation, diagnostic criteria, and therapeutic guidelines for managing malignant hyperthermia, emphasizing the critical importance of early recognition by anesthesiologists.
Answers are grounded in this paper and cite their sources.
Reinforces perioperative vigilance for malignant hyperthermia; leaves open prospective validation of diagnostic thresholds.
Malignant hyperthermia is a potentially lethal inherited disorder characterized by disturbance of calcium homeostasis in skeletal muscle. Volatile anesthetics and/or the depolarizing muscle relaxant succinylcholine may induce this hypermetabolic muscular syndrome due to uncontrolled sarcoplasmic calcium release via functionally altered calcium release receptors, resulting in hypoxemia, hypercapnia, tachycardia, muscular rigidity, acidosis, hyperkalemia, and hyperthermia in susceptible individuals. Since the clinical presentation of malignant hyperthermia is highly variable, survival of affected patients depends largely on early recognition of the symptoms characteristic of malignant hyperthermia, and immediate action on the part of the attending anesthesiologist. Clinical symptoms of malignant hyperthermia, diagnostic criteria, and current therapeutic guidelines, as well as adequate management of anesthesia in patients susceptible to malignant hyperthermia, are discussed in this review.
No takes yet. Share an insight, caveat, or question.
Schuster et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: